Marketing approval of mogamulizumab

EB66 cell line, a duck embryonic stem cell-derived substrate for the industrial production of therapeutic monoclonal antibodies with enhanced ADCC activity

(2014) Stéphane Olivier et al.   mAbs

Biosimilar, Biobetter, and Next Generation Antibody Characterization by Mass Spectrometry

(2012) Alain Beck et al.   ANALYTICAL CHEMISTRY

Isotype and glycoform selection for antibody therapeutics

(2012) Roy Jefferis   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies

(2012) L. H. Sehn et al.   BLOOD

An innovative approach for the characterization of the isoforms of a monoclonal antibody product

(2012) Shanmuuga Sundaram et al.   mAbs

7th Annual European Antibody Congress 2011

(2012) Alexey A. Lugovskoy et al.   mAbs

Galactosylation variations in marketed therapeutic antibodies

(2012) T. Shantha Raju et al.   mAbs

Lepidopteran cells, an alternative for the production of recombinant antibodies?

(2012) Martine Cérutti et al.   mAbs

Marketed therapeutic antibodies compendium

(2012) Janice M. Reichert   mAbs

An afucosylated anti-CD20 monoclonal antibody with greater antibody-dependent cellular cytotoxicity and B-cell depletion and lower complement-dependent cytotoxicity than rituximab

(2012) John R. Gasdaska et al.   MOLECULAR IMMUNOLOGY

GMP issues for recombinant plant-derived pharmaceutical proteins

(2011) Rainer Fischer et al.   BIOTECHNOLOGY ADVANCES

Modulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose

(2011) Michael J. Gramer et al.   BIOTECHNOLOGY AND BIOENGINEERING

Effects of cell culture conditions on antibody N-linked glycosylation-what affects high mannose 5 glycoform

(2011) Efren Pacis et al.   BIOTECHNOLOGY AND BIOENGINEERING

High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans

(2011) A. M. Goetze et al.   GLYCOBIOLOGY

Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors

(2011) Luis G. Paz-Ares et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors

(2011) Chong Wang et al.   mAbs

2nd Charles Richet et Jules Héricourt Workshop

(2011) Arnaud Daguet et al.   mAbs

Anti-cetuximab IgE ELISA for identification of patients at a high risk of cetuximab-induced anaphylaxis

(2011) Delphine Mariotte et al.   mAbs

Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study

(2011) Ningyan Zhang et al.   mAbs

Anti-galactose-α-1,3-galactose IgE from allergic patients does not bind α-galactosylated glycans on intact therapeutic antibody Fc domains

(2011) Jeroen J Lammerts van Bueren et al.   NATURE BIOTECHNOLOGY

Glycoprotein production in moss bioreactors

(2011) Eva L. Decker et al.   PLANT CELL REPORTS

Production of therapeutic antibodies with controlled fucosylation

(2010) Naoko Yamane-Ohnuki et al.   mAbs

Evolution of anti- CD20 monoclonal antibody therapeutics in oncology

(2010) Ezogelin Oflazoglu et al.   mAbs

Assessing monoclonal antibody product quality attribute criticality through clinical studies

(2010) Andrew M. Goetze et al.   mAbs

Engineered therapeutic antibodies with improved effector functions

(2009) Tsuguo Kubota et al.   CANCER SCIENCE

GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins

(2009) Alain Beck et al.   Expert Opinion on Drug Discovery

Trends in Glycosylation, Glycoanalysis and Glycoengineering of Therapeutic Antibodies and Fc-Fusion Proteins

(2008) Alain Beck et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY